iRhythm Technologies, Inc. (NASDAQ:IRTC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August10, 2017, the Board of Directors (the “Board”) of iRhythm Technologies, Inc. (the “Company”), upon recommendation of its Compensation Committee (the “Committee”) and in consultation with the Company’s independent compensation consultant, Compensia, Inc., approved certain changes to the Company’s Change of Control Severance Agreement and provided for additional severance benefits to be payable to Kevin M. King, the Company’s President and Chief Executive Officer, Matthew C. Garrett, the Company’s Chief Financial Officer, Derrick Sung, the Company’s Executive Vice President, Strategy and Corporate Development and David Vort, the Company’s Executive Vice President, Sales (collectively the “Named Executive Officers”). If the Company’s Chief Executive Officer experiences a qualifying termination outside of a Change of Control Period (as defined in the Company’s Change of Control and Severance Agreement filed with the U.S. Securities and Exchange Commission as Exhibit 10.29 to the Company’s Registration Statement filed on Form S-1 on September23, 2016), he shall now receive continuing payments of base salary severance for 18 months as compared to the 12 months that he was previously entitled to, and the Company will pay the Chief Executive Officer’s group health insurance provider the premiums necessary to continue group health insurance benefits for 18 months as compared to the 12 months that he was previously entitled to. In addition, all of our Named Executive Officers will now receive a lump sum payment, less applicable withholdings, equal to their target bonus amount if they experience a qualifying termination within the Change of Control Period. Finally, the Company moved Derrick Sung from Tier 3 to Tier 2 and provided him with the severance benefits consistent with a Tier 2 level employee under the Change of Control and Severance Agreement. The changes in severance benefits described above are effective September1, 2017.

On August10, 2017, director Vijay K. Lathi was appointed to the Company’s Nominating and Corporate Governance Committee.

About iRhythm Technologies, Inc. (NASDAQ:IRTC)

iRhythm Technologies, Inc. is a United States-based digital health company. The Company develops and commercializes solutions that integrate biosensor technology, patient data, analytics and medical expertise. The Company offers flagship solution, the ZIO Service. Its ZIO Service consists of the ZIO XT Patch, algorithms and the ZIO Report. Its myZIO provides a way for patients to enter their symptoms as they occur and on-the-go while wearing the ZIO Patch. Its ZIO Event Card is indicated for use on patients who experience transient symptoms, such as syncope, palpitations, and shortness of breath or dizziness. Its ZIO XT Patch is a non-invasive, water-resistant heart monitor, which prompts high patient compliance and a higher diagnostic yield. Its algorithms analyze the amounts of captured heart beat data and a concise report is provided to the patient’s physician. Its ZIO Report produces a higher diagnostic yield and to change patient management.